INTRODUCTION
The majority of adults with acute myeloid leukemia (AML) will need reinduction ('salvage') treatment because of failure of initial chemotherapy or relapse from complete remission (CR). 1, 2 Although numerous regimens containing cytarabine ⩾ 1 g/m 2 per dose (e.g. MEC (mitoxantrone, etoposide, cytarabine), 3 FLAG (fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF))) have been tested for this purpose, response rates have been low, particularly if the prior CR was short (o6-12 months) or the disease was refractory to prior therapy. [4] [5] [6] Increasing evidence highlights the importance of epigenetic modification in the pathogenesis of myeloid neoplasms. [7] [8] [9] [10] [11] Unlike DNA mutations, epigenetic changes can be pharmacologically reversed. Preclinical studies with the DNA methyltransferase (DNMT) inhibitors decitabine and azacitidine demonstrate dosedependent apoptosis in myeloid leukemia cells and synergistic cytotoxicity or chemosensitization when combined with conventional chemotherapeutics. [12] [13] [14] These effects appear greater if the DNMT inhibitors are used before ('priming'), rather than together with, the other chemotherapeutics. 13, 15 These observations, and studies showing the tolerability of decitabine combined with conventional chemotherapy, 16, 17 prompted a dose-escalation study of decitabine followed by MEC (dec/MEC). Our primary objectives were to determine the decitabine dose with the most favorable efficacy and toxicity profile when used as priming for MEC in adults receiving salvage therapy for AML or analogous malignancies and then to estimate the efficacy and toxicity profile of that dose in an expansion cohort.
PATIENTS AND METHODS

Study population
Adults aged ⩾ 18 years with relapsed/refractory AML (acute promyelocytic leukemia excepted) or other myeloid neoplasms with ⩾ 10% blasts in either peripheral blood and/or bone marrow were eligible if they had relapsed or refractory disease according to standard International Working Group Criteria 18 and a treatment-related mortality (TRM) score of ⩽ 9.2. This score, composed of weighted information from eight covariates (age, performance status, white blood cell count, peripheral blood blast percentage, type of AML (de novo vs secondary), platelet count, serum albumin and serum creatinine), corresponds to a ⩽ 9.2% probability of death within 28 days ('TRM') of receipt of intensive chemotherapy for newly diagnosed AML. 19 Patients were also required to have a left ventricular ejection fraction ⩾ 40%, creatinine ⩽ 1.5 times the institutional upper limit of normal and bilirubin ⩽ 2.5 times the institutional upper limit of normal. An expected survival of o1 year from another illness, uncontrolled infection or treatment with other investigational agents (including treatment with tyrosine kinase ('FLT3') inhibitors) were exclusions. Prior autologous or allogeneic hematopoietic cell transplantation (HCT) was permitted provided any graft-versus-host disease was well controlled with stable use of immunosuppressive agents, as was prior use of DNMT inhibitors or MEC (but not in combination). Cytogenetic risk was assessed according to the modified United Kingdom Medical Research Council/National Cancer Research Institute criteria. 20 Treatment responses were defined according to standard criteria. 18 Measurable ('minimal') residual disease (MRD) was assessed by multiparametric flow cytometry, with any level of MRD considered positive (MRD pos ). 21, 22 Relapse after study treatment was defined by standard morphologic criteria 18 or emergence of MRD after MRD negativity was achieved if this finding led to therapeutic intervention. The protocol (registered as NCT01729845) was approved by the Fred Hutchinson Cancer Research Center (Fred Hutch) Institutional Review Board (IRB), and patients gave written informed consent in accordance with the Declaration of Helsinki. Six patients who were otherwise eligible (TRM scores ⩽ 9.2) received dec/MEC outside this clinical trial during the study period.
Treatment plan
In phase 1, patients were assigned to intravenous decitabine (20 mg/m 2 per day) for 5, 7 or 10 days. Following a 5-day break, patients then received standard dose MEC (mitoxantrone 8 mg/m 2 per day intravenously on days 1-5; etoposide 100 mg/m 2 per day intravenously on days 1-5; cytarabine 1 g/m 2 per day intravenously on days 1-5). In phase 2, patients received the recommended phase 2 dose (RP2D) of decitabine identified in phase 1. No dose adjustments were made for age or any other baseline characteristic. Patients who did not achieve a CR or CR with incomplete platelet recovery (CRp) after the first course of dec/MEC were eligible to receive a second identical induction course. Patients achieving a CR/CRp with 1-2 cycles of dec/MEC could receive up to two postremission courses of dec/MEC given at the same doses as the induction cycle(s). Patients were taken off study for lack of CR/CRp achievement after two cycles of therapy, consolidation with HCT, excess toxicity including persistent aplasia without evidence of leukemia after day 45 of treatment, or relapse on therapy. Toxicities were evaluated based on the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 4.03 (http://ctep.cancer. gov).
Comparison of dec/MEC with other intensive reinduction chemotherapy regimens Two commonly used salvage regimens at our institution include G-CLAC (G-CSF 5 μg/kg subcutaneously from day 0 until neutrophil recovery; clofarabine 15-25 mg/m 2 per day intravenously on days 1-5; cytarabine 2 g/m 2 per day intravenously on days 1-5) 23 and G-CLAM (G-CSF 300 or 480 μg subcutaneously on days 0-5; cladribine 5 mg/m 2 per day intravenously on days 1-5; cytarabine 2 g/m 2 per day intravenously on days 1-5; mitoxantrone 10 mg/m 2 per day intravenously on days 1-3). 24, 25 Patients received G-CLAC either as part of a phase 1/2 study (NCT00602225) or off-protocol; all patients given G-CLAM at this dose level were treated outside a clinical study. Covariates collected included age, sex, cytogenetic risk, primary vs secondary disease, prior HCT, duration of first CR, performance status, TRM score, white blood cell and platelet count, peripheral blood blast percentage, FLT3 and NPM1 mutational status and whether or not treatment occurred as part of a clinical trial. This retrospective analysis was approved by the Fred Hutch IRB.
Statistical considerations
Phase 1. Cohorts of six patients were assigned to increasing days of decitabine therapy. Dose-limiting toxicity (DLT) was defined as: (1) any grade 3 non-hematologic toxicity lasting 448 h that resulted in a 47-day delay of the subsequent treatment cycle, with the exception of febrile neutropenia or infection; (2) any grade ⩾ 4 non-hematologic toxicity, with the exception of febrile neutropenia or infection or constitutional symptoms, if recovery to grade ⩽ 2 within 14 days. Maximum-tolerated dose was defined as the highest dose studied in which the incidence of DLTs was o33% (2/6 of each patient cohort). To better define safety and initial evidence of antileukemic activity, any dose level cohort could be expanded up to 12 patients, provided that ⩽ 2/6 patients had DLT at that dose level. Phase 1: Determination of safety and tolerability of dec/MEC Thirty patients were enrolled in the dose-escalation portion of this study and received a median of 1 (range: 1-2) cycles of therapy (Supplementary Table 1 ). As summarized in Table 2 , one DLT occurred at each of the second and third dose level (respiratory failure with shock and multisystem organ failure in both). Thus, all dose levels had acceptable toxicity based on our DLT/maximumtolerated dose definition. Adverse events by dose levels for the phase 1 patient cohort are summarized in Supplementary Table 2 . Nine of the 30 patients achieved a CR (30%, 95% exact confidence interval (CI): 15-49%), of which seven were negative for MRD (MRD neg ). Five additional patients achieved a CRp (three MRD neg ) for an ORR of 47% (95% CI: 28-66%). One other patient achieved an MRD pos CR with incomplete neutrophil recovery (CRi), three achieved a morphologic leukemia-free state (MLFS), four died early from indeterminate cause (i.e. died before a treatment response was assessed), and eight had resistant disease. Six of the 30 patients died within 28 days of treatment initiation because of respiratory failure in the setting of pneumonia (n = 2), sepsis and multisystem organ failure (n = 3), or intracranial hemorrhage (n = 1). Because of the relatively high TRM and the lack of obvious differences in response rates between the 7-and 10-day course of decitabine, 7-day priming with decitabine before MEC was declared the RP2D.
Phase 2: Estimation of antileukemia efficacy of dec/MEC Overall, we treated 46 patients at/above the RP2D, including 34 and 12 patients who received priming with 7 and 10 days of decitabine before MEC, respectively (Table 1 ). Best responses after 1-2 cycles of induction chemotherapy for the entire study population as well as those treated at/above the RP2D are summarized in Table 3 . Ten of the 46 (22%, 95% CI: 11-36%) achieved a CR (eight MRD neg ), and five obtained a CRp (11%, 95% CI: 4-24%), for an ORR of 33% (95% CI: 20-48%). Eleven of the 15 responders (73%) were negative for MRD, for an MRD neg ORR of 24% (95% CI: 13-39%). One further patient achieved an MRD pos CRi (2%, 95% CI: 0-12%), 7 patients obtained a MLFS (3 MRD neg ), 20 patients had resistant disease and 3 patients died from indeterminate cause/in aplasia. Restriction to the 34 patients treated at the 7-day dose level of decitabine yielded very similar results. Table 4 summarizes associations between baseline characteristics and induction response for the patients treated at/above the RP2D. While limited by the small sizes of individual patient subsets, we found higher response rates in patients with longer durations of their first CR, patients receiving dec/MEC as first salvage therapy, patients with favorable/intermediate-risk cytogenetics, and possibly those who did not receive prior therapy with intermediate-/high-dose cytarabine. In contrast, we found no strong evidence that response rates differed depending on patient age or history of prior allogeneic HCT. Response rates were not lower, and perhaps even higher, in patients with secondary disease.
Seven patients treated at/above the RP2D died within 28 days of treatment initiation because of respiratory failure in the setting of pneumonia (n = 1), sepsis and multisystem organ failure (n = 4), intracranial hemorrhage (n = 1) and progressive disease (n = 1), for a TRM rate of 15% (95% CI: 6-29%). Cytopenias, infections and neutropenic fever were the most common grade 3-5 toxicities. Grade 3-4 mucositis, gastrointestinal problems and hypoxia/ respiratory failure were also common, the latter usually associated with pneumonia (Table 5 and Supplementary Table 3 ).
Eleven of the 15 patients achieving a CR/CRp at doses at/above the RP2D received alternate postremission therapy (allogeneic HCT in 7). The other four discontinued study therapy owing to relapse (n = 1) or death while in remission (n = 3, with deaths attributed to infection during postremission therapy with dec/ MEC, infection in the setting of high doses of steroids used to treat graft-versus-host disease and an unrelated malignancy). Relapses occurred in 10 of the 15 patients (median CR duration: 246 (range 28-1031) days) and death in CR in 5 (after CR durations of 20, 20, 23, 61 and 107 days), including the 3 patients noted above and 2 patients who died from septic shock and unknown cause after completion of study therapy. For the cohort of 46 patients treated at/above the RP2D, these results translated into a median overall and relapse-free survival of 148 and 144 days, respectively ( Figure 1 ). For the patients alive at day 110 from study therapy (the maximum time to best response among all patients), the median survival for responders (n = 12) was 403 days compared with 190 days in the patients who failed to achieve a CR/CRp but did not experience early death (n = 17; P = 0.096). In total, 13 of the 46 patients (28%) treated at/above the RP2D underwent allogeneic HCT after receipt of dec/MEC, including 6 in CR/CRp at the time of transplant, 4 with persistent disease and 3 with MLFS. Median time from the start of dec/MEC therapy to transplant was 100 (range: 67-207) days. For these 13 patients, the median overall survival after transplant was 8 months (1-year survival: 26.5%). Among the six patients in CR/CRp at the time of transplant, median overall and relapse-free survival after transplant was 9 and 6 months (1-year survival: 33%; 1-year relapse-free survival: 33%), respectively. Among the seven patients not in CR/ CRp at the time of transplant, median survival after transplant was only 1 month (1-year survival: 21%).
Given specific concern about increased treatment-related toxicity in older patients and those who previously had recieved intermediate-/high-dose cytarabine-containing regimens, we performed additional exploratory subset analyses. For the 32 patients aged o60 years treated with dec/MEC at/above the RP2D, the CR/ CRp rate was 8/32 (25%), the 8-week mortality was 25% and the median survival was 4 months (1-year survival: 10%). These outcomes did not appear worse for the 14 patients ⩾ 60 years, with a CR/CRp rate of 7/14 (50%), an 8-week mortality of 1/14 (7%) and a median survival of 9 months (1-year survival: 36%). However, for the 10 patients aged o 60 years who underwent subsequent allogeneic HCT, the median survival after transplant was 7 months (1-year survival: 36%), whereas for the 3 patients 460 years who underwent HCT, the median survival after transplant was 3 months (1-year survival: 0%). Survival appeared slightly worse in the 25 patients who received prior intermediate-/ Abbreviations: AML, acute myeloid leukemia; ALT, alanine transaminase; AST, aspartate transaminase; CR1, first complete remission; FLAG-Ida, fludarabine, cytarabine, idarubicin, and filgrastim; G-CLAM, G-CSF; cladribine; cytarabine; mitoxantrone; G-CLAC, G-CSF; clofarabine; cytarabine; HCT, hematopoietic cell transplantation; HiDAC, high-dose cytarabine; IAP, idarubicin, high-dose cytarabine, pravastatin; MDS, myelodysplastic syndrome; RP2D, recommended phase 2 dose; TRM, treatment-related mortality; WBC, white blood cell. a AML transformed from antecedent hematologic disorder or AML/MDS after prior cytotoxic therapy. Duration of cytopenias Data on duration of neutropenia and thrombocytopenia may be most informative (and least confounded by residual leukemia) in patients who achieved a CR. Among the 10 patients who achieved a CR after receipt of dec/MEC at/above the RP2D, the median time to recovery of absolute neutrophil count 41000 and platelets 4100 000 was 29 (range: 27-66) and 29 (range: 20-66) days, respectively. When restricting this analysis to the eight patients who achieved an MRD neg CR, median time to recovery of absolute neutrophil count 41000 and platelets 4100 000 was 30 (range: 27-66) and 29 (range: 26-66) days, respectively.
Comparison with other salvage regimens As this was a single-arm trial, we compared the outcomes observed on this trial to those obtained with other salvage regimens, controlling for prognostic factors. First, for each patient given dec/MEC, we calculated a probability of CR based on prior CR duration (primary refractory = 0) and number of salvage regimens. Summing these probabilities indicated that 5.6 of the 46 patients would have been expected to enter CR with the salvage regimens used at MD Anderson in the 1990s (mainly including high-dose cytarabine). 27 Since we observed 10 CRs in these 46 patients, the observed/expected (O/E) CR ratio was 1.77. This O/E method is not amenable to multivariable statistical analysis. Hence, we also compared study results with outcomes from two contemporary patient cohorts, one receiving G-CLAC 23 and the other receiving G-CLAM. 24, 25 For these comparisons, we included the dec/MEC patients treated at/above the RP2D as well as six additional patients who received dec/MEC outside this clinical trial for logistical reasons, but met all the study inclusion/ exclusion criteria, and restricted the G-CLAC and G-CLAM cohorts Decitabine/MEC in relapsed/refractory AML/MDS AB Halpern et al to patients with relapsed/refractory AML and TRM scores ⩽ 9.2. Basic characteristics of these three study cohorts are summarized in Table 6 . In univariate analysis, patients treated with G-CLAC and G-CLAM were more likely to achieve a CR/CRp (odds ratio (OR) of 2.26 and 2.30; P = 0.04 and 0.06, respectively). After controlling for various prognostic factors via multivariable analysis, treatment with G-CLAC or G-CLAM was associated with higher CR/CRp rates (for G-CLAC: OR = 2.40 (95% CI: 0.87-6.64), P = 0.09; for G-CLAM: OR = 2.80 (95% CI: 0.96-8.17), P = 0.06). Median survival was 4.9 months for dec/MEC, 5.2 months for G-CLAC and 8.1 months for G-CLAM (Figure 2) . In multivariable analysis, the hazard ratio for death was 0.69 for G-CLAC (95% CI: 0.42-1.14, P = 0.15) and 0.9 for G-CLAM (95% CI: 0.53-1.52, P = 0.69) compared with dec/MEC.
DISCUSSION
In this study, we explored the sequential use of decitabine and MEC based on the premise that priming with a DNMT inhibitor sensitizes AML cells to conventional chemotherapeutics. Our limited ex vivo experiments indicated that this sensitizing effect is greater with delayed use of chemotherapy agents (DLS, unpublished observation). Consistent with this observation are Kantarjian et al.'s 28 findings from correlative analyses of specimens from patients with myelodysplastic syndrome participating in a phase 3 trial demonstrating extended demethylation in peripheral blood cells after decitabine treatment. With a CR/CRp rate of 33% for patients treated at/above the R2PD, the dec/MEC regimen met our prespecified efficacy goal of 'being worthy of further investigation'. Many of the responders were subsequently able to undergo allogeneic HCT, the preferred curative-intent treatment option for relapsed or refractory disease. Still, although we selected a medically fit subset of patients for dec/MEC therapy, we noted a relatively high early mortality (TRM) rate, highlighting the difficulties in administering intense cytotoxic therapy in previously treated AML/MDS patients.
Our study was limited in that it followed a traditional single-arm design and did not include a control group. To address this, we compared outcomes with dec/MEC with those of a historical control population that we matched based on duration of prior remission and number of prior salvage therapies, 27 and obtained an observed/expected CR ratio that favored dec/MEC, indeed suggesting value of this combination regimen. However, this approach can be criticized for the 'historic' nature of the control patient population, which was treated between 1991 and 1994. 27 We therefore additionally compared study results with outcomes from two contemporary patient cohorts who received high-dose cytarabine-based salvage chemotherapy, G-CLAC or G-CLAM, salvage regimens commonly used at our institution since 2008. After controlling for various prognostic factors via multivariable analysis, we found the response rates with dec/MEC to be no better (and, in fact, to be likely slightly worse) than with G-CLAC or G-CLAM, whereas survival estimates were similar for all three patient cohorts after multivariable adjustments. This may be partly due to the higher TRM rate with dec/MEC than G-CLAC or G-CLAM in our patient cohorts. Specifically, despite very similar baseline TRM scores in all three cohorts (median (range) for dec/MEC: 3.8 (0.1-9.1); for G-CLAM: 3.5 (0.1-9.1); for G-CLAC: 3.5 (0.2-9.2)), early death rates varied substantially (dec/MEC: 15%; for G-CLAM: 7%; for G-CLAC: 0%; see Table 6 ). We were unable to identify particular patient-or disease-specific characteristics that would account for these differences between treatment cohorts, and we can only speculate that they may be due to comorbidities not accurately captured in the TRM score, which was originally developed in patients with newly diagnosed (not relapsed/refractory) AML. Still, these data suggest no obvious advantage of dec/MEC over other contemporary high-dose cytarabine-based salvage regimens and highlight the need for controlled assessments of antileukemia efficacies of experimental treatment regimens. 29 Also, the difference in conclusion one would draw from the historic patient comparison and the comparison with contemporary patients stresses the importance of including appropriate control patients in the design of trials testing new therapies for AML. 29 The clinical value of combining DNMT inhibitors with conventional chemotherapeutics remains uncertain. So far, several studies have examined combinations of decitabine and cytotoxic chemotherapy for AML. In a phase 1 trial, decitabine priming followed by daunorubicin and cytarabine ('3+7') for patients with de novo, unfavorable risk AML was well tolerated, and no DLTs were reached when doses of decitabine were escalated. 16 More recently, decitabine was used both sequentially with G-CSF, idarubicin and low-dose cytarabine 30 or G-CSF, aclarubicin and low-dose cytarabine, 31 as well as concurrently with aclacinomycin and cytarabine. 17 In these studies, it was felt that outcomes were better than what would have been expected without the use of decitabine. In contrast, a study that investigated the value of adding azacitidine before 3+7 chemotherapy in a randomized manner in 214 older adults (median age: 70 years) with newly diagnosed AML found no differences in efficacy but increased toxicity in the combination arm. 32 As we did not have a contemporary cohort of patients with relapsed/refractory AML receiving MEC as salvage therapy, we were unable to determine whether dec/MEC provided any benefit over MEC.
Dec/MEC showed antileukemia activity that was comparable to other contemporary salvage regimens in this challenging patient population, which continues to have a poor prognosis with currently used treatments. A follow-up study at our institution will explore decitabine together with G-CLAM in newly diagnosed as well as relapsed/refractory AML (NCT02921061), with nonrandomized comparison of trial results to outcomes with G-CLAM alone. This study will assess the importance of decitabine timing relative to G-CLAM by randomizing patients to receive decitabine sequentially or concurrently with G-CLAM. 
